Mainz Biomed announced its commercial partnership for ColoAlert with Fugene Genetics, a genetic testing service provider based in Israel. Fugene Genetics, established in 2008, offers a wide range of advanced genetic testing services to private clients, health organizations, hospitals, and genetic institutes throughout the country. ColoAlert is Mainz Biomed’s flagship product, an effective and user-friendly at-home detection test for colorectal cancer, or CRC. The test is currently being rolled out in Europe and selected international markets through a unique business model of partnering with third-party laboratories and experienced distribution partners for test kit processing, as opposed to operating a single facility, which is the traditional approach.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on MYNZ:
- Mainz Biomed Announces Collaboration with Fugene Genetics in Israel
- Mainz Biomed Secures up to $50M in New Funding
- Mainz Biomed to Attend ESMO World Congress on Gastrointestinal Cancer 2023 in Barcelona, Spain
- Mainz Biomed expands into Romania with Bioclinica partnership
- Mainz Biomed Expands into Romania Through Partnership with Bioclinica